Skip to content

Trading statement Q1-2024: CEO video statement

Strong start and raised expectation to the full year 2024

Results from the first quarter of 2024 show a strong start for Gubra. Revenue in our CRO business grew organically by 51% year-over-year. In Discovery and Partnerships, we are on track with the clinical phase 1 trial of our Amylin-based anti-obesity asset. Recent announcement to progress our new healthy weight loss drug candidate Urocortin-2 further towards the clinic and a raised financial outlook for 2024 are just a few highlights from the first trading statement this year.

Watch this video with our CEO Henrik Blou where he covers all the main developments in just about 4 minutes.

Contacts at Gubra
Media: Sofia Pitt Boserup, [email protected], +45 4188 9586
Investors: Kristian Borbos, [email protected], +45 3080 8035

Share this page

For further information

Contact us


Hørsholm Kongevej 11B
2970 Hørsholm

[email protected]
+45 3152 ­2650

Back To Top